Viridian’s $150M offering; Surrozen scraps IBD drug candidate; Assembly ends deal with Indiana University
Plus, news about Vor Bio, Vaxxinity, Immatics and Certis Oncology:
Viridian Therapeutics’ $150M public offering: The Waltham, MA-based biotech is selling …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
